Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies
European Journal of Cancer · 2024-03 · 200 · 113587
DOI: 10.1016/j.ejca.2024.113587 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2024-03. Verfasst von Alessandro Parisi und 44 weiteren Autor:innen. Beteiligte Einrichtung: Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Vi…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Morpholines, Pyrimidines. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Pemigatinib is approved for patients with pretreated, locally advanced or metastatic CCA harboring FGFR2 rearrangements or fusions. We aim to assess the effectiveness and safety of pemigatinib in real-world setting. MATERIAL AND METHODS: A joint analysis of two multicentre observational retrospective cohort studies independently conducted in France and Italy was performed. All consecutive FGFR2-positive patients affected by CCA and treated with pemigatinib as second- or further line of systemic treatment in clinical practice, within or outside the European Expanded Access Program, were included. RESULTS: Between July 2020 and September 2022, 72 patients were treated with pemigatinib in 14 Italian and 25 French Centres. Patients had a median age of 57 years, 76% were female, 81% had ECOG-PS 0-1, 99% had intrahepatic CCA, 74% had ≥ 2 metastatic sites, 67% had metastatic disease at diagnosis, while 38.8% received ≥ 2 previous lines of systemic treatment. At data cut-off analysis (April 2023), ORR and DCR were 45.8% and 84.7%, respectively. Median DoR was 7 months (IQR: 5.8-9.3). Over a median follow-up time of 19.5 months, median PFS and 1-year PFS rate were 8.7 months and 32.8%. Median OS and 1-year OS rate were 17.1 months and 60.6%. Fatigue (69.4%), ocular toxicity (68%), nail toxicities (61.1%), dermatologic toxicity (41.6%) hyperphosphataemia (55.6%), stomatitis (48.6%), and diarrhea (36.1%) were the most frequent, mainly G1-G2 AEs. Overall incidence of G3 AEs was 22.2%, while no patient experienced G4 AE. Dose reduction and temporary discontinuation were needed in 33.3% and 40.3% of cases, with 1 permanent discontinuation due to AEs. CONCLUSIONS: These results confirm the effectiveness and safety of pemigatinib in a real-world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy. Electronic address: alexparis@hotmail…
- Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy; Digestive Oncology Department, Centre…
- Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy.
- Département d'Innovation Thérapeutique et Essais précoces (DITEP), Gustave Roussy, Villejuif Cedex, France.
- Oncology Digestive Unit, Hôpital haut-Lévêque, CHU Bordeaux France, France.
- Liver Oncology and Therapeutic Innovation Functional Unit, Beaujon Hospital APHP, Clichy, France.
Zitieren
APA
Parisi, A., Delaunay, B., Pinterpe, G., Hollebecque, A., Blanc, J. F., Bouattour, M., Assenat, E., Ben Abdelghani, M., Sarabi, M., Niger, M., Vivaldi, C., Mandalà, M., Palloni, A., Bensi, M., Garattini, S. K., Tougeron, D., Combe, P., Salati, M., Rimini, M., …, & Fares, N. (2024). Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies. European Journal of Cancer, 200, 113587. https://doi.org/10.1016/j.ejca.2024.113587
Vancouver
Parisi A, Delaunay B, Pinterpe G, Hollebecque A, Blanc JF, Bouattour M, et al. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies. European Journal of Cancer. 2024;200:113587. doi:10.1016/j.ejca.2024.113587
BibTeX
@article{Parisi2024,
author = {Parisi, Alessandro and Delaunay, Blandine and Pinterpe, Giada and Hollebecque, Antoine and Blanc, Jean Frederic and Bouattour, Mohamed and Assenat, Eric and Ben Abdelghani, Meher and Sarabi, Matthieu and Niger, Monica and Vivaldi, Caterina and Mandalà, Mario and Palloni, Andrea and Bensi, Maria and Garattini, Silvio Ken and Tougeron, David and Combe, Pierre and Salati, Massimiliano and Rimini, Margherita and Cella, Chiara Alessandra and Tucci, Marco and Diana, Anna and Mori, Elena and Longarini, Raffaella and Artru, Pascal and Roth, Gael and Evesque, Ludovic and Vienne, Agathe and Turpin, Anthony and Hiret, Sandrine and Bourgeois, Vincent and Herve, Camille and Paulon, Rodolphe and Stacoffe, Marion and Malka, David and Neuzillet, Cindy and Edeline, Julien and Lievre, Astrid and Guimbaud, Rosine and Chapda, Marie Christelle Pajiep and Rimassa, Lorenza and Giampieri, Riccardo and Valle, Juan and Berardi, Rossana and Fares, Nadim},
title = {Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies},
journal = {European Journal of Cancer},
year = {2024},
volume = {200},
pages = {113587},
doi = {10.1016/j.ejca.2024.113587}
}
EUVIMED